US2007265290A1PendingUtilityA1
Heterocyclic selective androgen receptor modulators and methods of use thereof
Est. expiryOct 15, 2022(expired)· nominal 20-yr term from priority
A61P 5/26A61P 7/06A61P 5/28A61P 3/04A61P 25/28A61P 25/24A61P 35/00A61P 27/02A61P 15/00C07D 213/75A61P 15/16A61P 17/14A61P 19/10A61P 13/08A61P 15/10C07K 14/721C07D 213/84
55
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
This invention provides a class of androgen receptor targeting agents (ARTA). The agents define a new subclass of compounds, which are selective androgen receptor modulators (SARM). Several of the SARM compounds have been found to have an unexpected androgenic and anabolic activity of a nonsteroidal ligand for the androgen receptor. Other SARM compounds have been found to have an unexpected antiandrogenic activity of a nonsteroidal ligand for the androgen receptor. The SARM compounds, either alone or as a composition, are useful for a) male contraception; b) treatment of a variety of hormone-related conditions, for example conditions associated with Androgen Decline in Aging Male (ADAM), such as fatigue, depression, decreased libido, sexual dysfunction, erectile dysfunction, hypogonadism, osteoporosis, hair loss, anemia, obesity, sarcopenia, osteopenia, osteoporosis, benign prostate hyperplasia, alterations in mood and cognition and prostate cancer; c) treatment of conditions associated with Androgen Decline in Female (ADIF), such as sexual dysfunction, decreased sexual libido, hypogonadism, sarcopenia, osteopenia, osteoporosis, alterations in cognition and mood, depression, anemia, hair loss, obesity, endometriosis, breast cancer, uterine cancer and ovarian cancer; d) treatment and/or prevention of acute and/or chronic muscular wasting conditions; e) preventing and/or treating dry eye conditions; f) oral androgen replacement therapy; g) decreasing the incidence of, halting or causing a regression of prostate cancer; and/or h) inducing apoptosis in a cancer cell.
Claims
exact text as granted — not AI-modified1 . A method of binding a selective androgen receptor modulator compound to an androgen receptor, comprising the step of contacting the androgen receptor with the selective androgen receptor modulator compound represented by the structure of formula I:
wherein
X is a bond, O, CH 2 , NH, Se, PR, NO or NR;
G is O or S;
R 1 is CH 3 , CH 2 F, CHF 2 , CF 3 , CH 2 CH 3 , or CF 2 CF 3 ;
T is OH, OR, NHCOCH 3 , or NHCOR;
R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH 2 F, CHF 2 , CF 3 , CF 2 CF 3 , aryl, phenyl, F, Cl, Br, I, alkenyl or OH;
A is a ring selected from:
B is a ring selected from:
wherein A and B cannot simultaneously be a benzene ring;
Z is NO 2 , CN, COOH, COR, NHCOR or CONHR;
Y is CF 3 , F, I, Br, Cl, CN, C(R) 3 or Sn(R) 3 ;
Q 1 and Q 2 are independently of each other a hydrogen, alkyl, F, Cl, Br, I, CF 3 , CN, C(R) 3 , Sn(R) 3 , N(R) 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R, SR,
Q 3 and Q 4 are independently of each other a hydrogen, alkyl, F, Cl, Br, I, CF 3 , CN, CR 3 , SnR 3 , NR 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R or SR;
W 1 is O, NH, NR, NO or S; and
W 2 is N or NO.
or its isomer, pharmaceutically acceptable salt, hydrate, N-oxide or any combination thereof in an amount effective to bind the selective androgen receptor modulator compound to the androgen receptor.
2 . A method of suppressing spermatogenesis in a subject comprising contacting an androgen receptor of the subject with the selective androgen receptor modulator compound represented by the structure of formula I:
wherein
X is a bond, O, CH 2 , NH, Se, PR, NO or NR;
G is O or S;
R 1 is CH 3 , CH 2 F, CHF 2 , CF 3 , CH 2 CH 3 , or CF 2 CF 3 ;
T is OH, OR, —NHCOCH 3 , or NHCOR;
R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH 2 F, CHF 2 , CF 3 , CF 2 CF 3 , aryl, phenyl, F, Cl, Br, I, alkenyl or OH;
A is a ring selected from:
B is a ring selected from:
wherein A and B cannot simultaneously be a benzene ring;
Z is NO 2 , CN, COOH, COR, NHCOR or CONHR;
Y is CF 3 , F, I, Br, Cl, CN, C(R) 3 or Sn(R) 3 ;
Q 1 and Q 2 are independently of each other a hydrogen, alkyl, F, Cl, Br, I, CF 3 , CN, C(R) 3 , Sn(R) 3 , N(R) 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R, SR,
Q 3 and Q 4 are independently of each other a hydrogen, alkyl, F, Cl, Br, I, CF 3 , CN, CR 3 , SnR 3 , NR 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R or SR;
W 1 is O, NH, NR, NO or S; and
W 2 is N or NO.
or its isomer, pharmaceutically acceptable salt, hydrate, N-oxide or any combination thereof in an amount effective to suppress sperm production.
3 . A method of contraception in a male subject, comprising the step of administering to said subject the selective androgen receptor modulator compound represented by the structure of formula I:
wherein
X is a bond, O, CH 2 , NH, Se, PR, NO or NR;
G is O or S;
R 1 is CH 3 , CH 2 F, CHF 2 , CF 3 , CH 2 CH 3 , or CF 2 CF 3 ;
T is OH, OR, NHCOCH 3 , or NHCOR;
R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH 2 F, CHF 2 , CF 3 , CF 2 CF 3 , aryl, phenyl, F, Cl, Br, I, alkenyl or OH;
A is a ring selected from:
B is a ring selected from:
wherein A and B cannot simultaneously be a benzene ring;
Z is NO 2 , CN, COOH, COR, NHCOR or CONHR;
Y is CF 3 , F, I, Br, Cl, CN, C(R) 3 or Sn(R) 3 ;
Q 1 and Q 2 are independently of each other a hydrogen, alkyl, F, Cl, Br, I, CF 3 , CN, C(R) 3 , Sn(R) 3 , N(R) 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R, SR,
Q 3 and Q 4 are independently of each other a hydrogen, alkyl, F, Cl, Br, I, CF 3 , CN, CR 3 , SnR 3 , NR 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R or SR;
W 1 is O, NH, NR, NO or S; and
W 2 is N or NO.
or its isomer, pharmaceutically acceptable salt, hydrate, N-oxide or any combination thereof in an amount effective to suppress sperm production in said subject, thereby effecting contraception in said subject.
4 . A method of hormone therapy comprising the step of contacting an androgen receptor of a subject with the selective androgen receptor modulator compound represented by the structure of formula I:
wherein
X is a bond, O, CH 2 , NH, Se, PR, NO or NR;
G is O or S;
R 1 is CH 3 , CH 2 F, CHF 2 , CF 3 , CH 2 CH 3 , or CF 2 CF 3 ;
T is OH, OR, NHCOCH 3 , or NHCOR;
R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH 2 F, CHF 2 , CF 3 , CF 2 CF 3 , aryl, phenyl, F, Cl, Br, I, alkenyl or OH;
A is a ring selected from:
B is a ring selected from:
wherein A and B cannot simultaneously be a benzene ring;
Z is NO 2 , CN, COOH, COR, NHCOR or CONHR;
Y is CF 3 , F, I, Br, Cl, CN, C(R) 3 or Sn(R) 3 ;
Q 1 and Q 2 are independently of each other a hydrogen, alkyl, F, Cl, Br, I, CF 3 , CN, C(R) 3 , Sn(R) 3 , N(R) 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R, SR,
Q 3 and Q 4 are independently of each other a hydrogen, alkyl, F, Cl, Br, I, CF 3 , CN, CR 3 , SnR 3 , NR 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R or SR;
W 1 is O, NH, NR, NO or S; and
W 2 is N or NO.
or its isomer, pharmaceutically acceptable salt, hydrate, N-oxide or any combination thereof in an amount effective to effect a change in an androgen-dependent condition.
5 . A method of hormone replacement therapy comprising the step of contacting an androgen receptor of a subject with the selective androgen receptor modulator compound represented by the structure of formula I:
wherein
X is a bond, O, CH 2 , NH, Se, PR, NO or NR;
G is O or S;
R 1 is CH 3 , CH 2 F, CHF 2 , CF 3 , CH 2 CH 3 , or CF 2 CF 3 ;
T is OH, OR, NHCOCH 3 , or NHCOR;
R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH 2 F, CHF 2 , CF 3 , CF 2 CF 3 , aryl, phenyl, F, Cl, Br, I, alkenyl or OH;
A is a ring selected from:
B is a ring selected from:
wherein A and B cannot simultaneously be a benzene ring;
Z is NO 2 , CN, COOH, COR, NHCOR or CONHR;
Y is CF 3 , F, I, Br, Cl, CN, C(R) 3 or Sn(R) 3 ;
Q 1 and Q 2 are independently of each other a hydrogen,
alkyl, F, Cl, Br, I, CF 3 , CN, C(R) 3 , Sn(R) 3 , N(R) 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R, SR,
Q 3 and Q 4 are independently of each other a hydrogen, alkyl, F, Cl, Br, I, CF 3 , CN, CR 3 , SnR 3 , NR 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R or SR;
W 1 is O, NH, NR, NO or S; and
W 2 is N or NO.
or its isomer, pharmaceutically acceptable salt, hydrate, N-oxide or any combination thereof in an amount effective to effect a change in an androgen-dependent condition.
6 . A method of treating a subject having a hormone related condition, comprising the step of administering to said subject the selective androgen receptor modulator compound represented by the structure of formula I:
wherein
X is a bond, O, CH 2 , NH, Se, PR, NO or NR;
G is O or S;
R 1 is CH 3 , CH 2 F, CHF 2 , CF 3 , CH 2 CH 3 , or CF 2 CF 3 ;
T is OH, OR, NHCOCH 3 , or NHCOR;
R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH 2 F, CHF 2 , CF 3 , CF 2 CF 3 , aryl, phenyl, F, Cl, Br, I, alkenyl or OH;
A is a ring selected from:
B is a ring selected from:
wherein A and B cannot simultaneously be a benzene ring;
Z is NO 2 , CN, COOH, COR, NHCOR or CONHR;
Y is CF 3 , F, I, Br, Cl, CN, C(R) 3 or Sn(R) 3 ;
Q 1 and Q 2 are independently of each other a hydrogen, alkyl, F, Cl, Br, I, CF 3 , CN, C(R) 3 , Sn(R) 3 , N(R) 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R, SR,
Q 3 and Q 4 are independently of each other a hydrogen, alkyl, F, Cl, Br, I, CF 3 , CN, CR 3 , SnR 3 , NR 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R or SR;
W 1 is O, NH, NR, NO or S; and
W 2 is N or NO.
or its isomer, pharmaceutically acceptable salt, hydrate, N-oxide or any combination thereof in an amount effective to effect a change in an androgen-dependent condition.
7 . A method of treating a subject suffering from prostate cancer, comprising the step of administering to said subject the selective androgen receptor modulator compound represented by the structure of formula I:
wherein
X is a bond, O, CH 2 , NH, Se, PR, NO or NR;
G is O or S;
R 1 is CH 3 , CH 2 F, CHF 2 , CF 3 , CH 2 CH 3 , or CF 2 CF 3 ;
T is OH, OR, NHCOCH 3 , or NHCOR;
R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH 2 F, CHF 2 , CF 3 , CF 2 CF 3 , aryl, phenyl, F, Cl, Br, I, alkenyl or OH;
A is a ring selected from:
B is a ring selected from:
wherein A and B cannot simultaneously be a benzene ring;
Z is NO 2 , CN, COOH, COR, NHCOR or CONHR;
Y is CF 3 , F, I, Br, Cl, CN, C(R) 3 or Sn(R) 3 ;
Q 1 and Q 2 are independently of each other a hydrogen, alkyl, F, Cl, Br, I, CF 3 , CN, C(R) 3 , Sn(R) 3 , N(R) 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R, SR,
Q 3 and Q 4 are independently of each other a hydrogen, alkyl, F, Cl, Br, I, CF 3 , CN, CR 3 , SnR 3 , NR 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R or SR;
W 1 is O, NH, NR, NO or S; and
W 2 is N or NO.
or its isomer, pharmaceutically acceptable salt, hydrate, N-oxide or any combination thereof in an amount effective to treat prostate cancer in said subject.
8 . A method of preventing prostate cancer in a subject, comprising the step of administering to said subject the selective androgen receptor modulator compound represented by the structure of formula I:
wherein
X is a bond, O, CH 2 , NH, Se, PR, NO or NR;
G is O or S;
R 1 is CH 3 , CH 2 F, CHF 2 , CF 3 , CH 2 CH 3 , or CF 2 CF 3 ;
T is OH, OR, NHCOCH 3 , or NHCOR;
R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH 2 F, CHF 2 , CF 3 , CF 2 CF 3 , aryl, phenyl, F, Cl, Br, I, alkenyl or OH;
A is a ring selected from:
B is a ring selected from:
wherein A and B cannot simultaneously be a benzene ring;
Z is NO 2 , CN, COOH, COR, NHCOR or CONHR;
Y is CF 3 , F, I, Br, Cl, CN, C(R) 3 or Sn(R) 3 ;
Q 1 and Q 2 are independently of each other a hydrogen, alkyl, F, Cl, Br, I, CF 3 , CN, C(R) 3 , Sn(R) 3 , N(R) 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R, SR,
Q 3 and Q 4 are independently of each other a hydrogen, alkyl, F, Cl, Br, I, CF 3 , CN, CR 3 , SnR 3 , NR 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R or SR;
W 1 is O, NH, NR, NO or S; and
W 2 is N or NO.
or its isomer, pharmaceutically acceptable salt, hydrate, N-oxide or any combination thereof in an amount effective to prevent prostate cancer in said subject.
9 . A method of delaying the progression of prostate cancer in a subject suffering from prostate cancer, comprising the step of administering to said subject the selective androgen receptor modulator compound represented by the structure of formula I:
wherein
X is a bond, O, CH 2 , NH, Se, PR, NO or NR;
G is O or S;
R 1 is CH 3 , CH 2 F, CHF 2 , CF 3 , CH 2 CH 3 , or CF 2 CF 3 ;
T is OH, OR, NHCOCH 3 , or NHCOR;
R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH 2 F, CHF 2 , CF 3 , CF 2 CF 3 , aryl, phenyl, F, Cl, Br, I, alkenyl or OH;
A is a ring selected from:
B is a ring selected from:
wherein A and B cannot simultaneously be a benzene ring;
Z is NO 2 , CN, COOH, COR, NHCOR or CONHR;
Y is CF 3 , F, I, Br, Cl, CN, C(R) 3 or Sn(R) 3 ;
Q 1 and Q 2 are independently of each other a hydrogen,
alkyl, F, Cl, Br, I, CF 3 , CN, C(R) 3 , Sn(R) 3 , N(R) 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R, SR,
Q 3 and Q 4 are independently of each other a hydrogen, alkyl, F, Cl, Br, I, CF 3 , CN, CR 3 , SnR 3 , NR 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R or SR;
W 1 is O, NH, NR, NO or S; and
W 2 is N or NO.
or its isomer, pharmaceutically acceptable salt, hydrate, N-oxide or any combination thereof in an amount effective to delay the progression of prostate cancer in said subject.
10 . A method of preventing the recurrence of prostate cancer in a subject suffering from prostate cancer, comprising the step of administering to said subject the selective androgen receptor modulator compound represented by the structure of formula I:
wherein
X is a bond, O, CH 2 , NH, Se, PR, NO or NR;
G is O or S;
R 1 is CH 3 , CH 2 F, CHF 2 , CF 3 , CH 2 CH 3 , or CF 2 CF 3 ;
T is OH, OR, NHCOCH 3 , or NHCOR;
R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH 2 F, CHF 2 , CF 3 , CF 2 CF 3 , aryl, phenyl, F, Cl, Br, I, alkenyl or OH;
A is a ring selected from:
B is a ring selected from:
wherein A and B cannot simultaneously be a benzene ring;
Z is NO 2 , CN, COOH, COR, NHCOR or CONHR;
Y is CF 3 , F, I, Br, Cl, CN, C(R) 3 or Sn(R) 3 ;
Q 1 and Q 2 are independently of each other a hydrogen, alkyl, F, Cl, Br, I, CF 3 , CN, C(R) 3 , Sn(R) 3 , N(R) 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R, SR,
Q 3 and Q 4 are independently of each other a hydrogen, alkyl, F, Cl, Br, I, CF 3 , CN, CR 3 , SnR 3 , NR 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R or SR;
W 1 is O, NH, NR, NO or S; and
W 2 is N or NO.
or its isomer, pharmaceutically acceptable salt, hydrate, N-oxide or any combination thereof in an amount effective to prevent the recurrence of prostate cancer in said subject.
11 . A method of treating the recurrence of prostate cancer in a subject suffering from prostate cancer, comprising the step of administering to said subject the selective androgen receptor modulator compound represented by the structure of formula I:
wherein
X is a bond, O, CH 2 , NH, Se, PR, NO or NR;
G is O or S;
R 1 is CH 3 , CH 2 F, CHF 2 , CF 3 , CH 2 CH 3 , or CF 2 CF 3 ;
T is OH, OR, NHCOCH 3 , or NHCOR;
R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH 2 F, CHF 2 , CF 3 , CF 2 CF 3 , aryl, phenyl, F, Cl, Br, I, alkenyl or OH;
A is a ring selected from:
B is a ring selected from:
wherein A and B cannot simultaneously be a benzene ring;
Z is NO 2 , CN, COOH, COR, NHCOR or CONHR;
Y is CF 3 , F, I, Br, Cl, CN, C(R) 3 or Sn(R) 3 ;
Q 1 and Q 2 are independently of each other a hydrogen, alkyl, F, Cl, Br, I, CF 3 , CN, C(R) 3 , Sn(R) 3 , N(R) 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R, SR,
Q 3 and Q 4 are independently of each other a hydrogen, alkyl, F, Cl, Br, I, CF 3 , CN, CR 3 , SnR 3 , NR 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R or SR;
W 1 is O, NH, NR, NO or S; and
W 2 is N or NO.
or its isomer, pharmaceutically acceptable salt, hydrate, N-oxide or any combination thereof in an amount effective to treat the recurrence of prostate cancer in said subject.
12 . A method of treating a dry eye condition in a subject suffering from dry eyes, comprising the step of administering to said subject the selective androgen receptor modulator compound represented by the structure of formula I:
wherein
X is a bond, O, CH 2 , NH, Se, PR, NO or NR;
G is O or S;
R 1 is CH 3 , CH 2 F, CHF 2 , CF 3 , CH 2 CH 3 , or CF 2 CF 3 ;
T is OH, OR, NHCOCH 3 , or NHCOR;
R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH 2 F, CHF 2 , CF 3 , CF 2 CF 3 , aryl, phenyl, F, Cl, Br, I, alkenyl or OH;
A is a ring selected from:
B is a ring selected from:
wherein A and B cannot simultaneously be a benzene ring;
Z is NO 2 , CN, COOH, COR, NHCOR or CONHR;
Y is CF 3 , F, I, Br, Cl, CN, C(R) 3 or Sn(R) 3 ;
Q 1 and Q 2 are independently of each other a hydrogen, alkyl, F, Cl, Br, I, CF 3 , CN, C(R) 3 , Sn(R) 3 , N(R) 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R, SR,
Q 3 and Q 4 are independently of each other a hydrogen, alkyl, F, Cl, Br, I, CF 3 , CN, CR 3 , SnR 3 , NR 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R or SR;
W 1 is O, NH, NR, NO or S; and
W 2 is N or NO.
or its isomer, pharmaceutically acceptable salt, hydrate, N-oxide or any combination thereof in an amount effective to treat dry eyes in said subject.
13 . A method of preventing a dry eye condition in a subject, comprising the step of administering to said subject the selective androgen receptor modulator compound represented by the structure of formula I:
wherein
X is a bond, O, CH 2 , NH, Se, PR, NO or NR;
G is O or S;
R 1 is CH 3 , CH 2 F, CHF 2 , CF 3 , CH 2 CH 3 , or CF 2 CF 3 ;
T is OH, OR, NHCOCH 3 , or NHCOR;
R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH 2 F, CHF 2 , CF 3 , CF 2 CF 3 , aryl, phenyl, F, Cl, Br, I, alkenyl or OH;
A is a ring selected from:
B is a ring selected from:
wherein A and B cannot simultaneously be a benzene ring;
Z is NO 2 , CN, COOH, COR, NHCOR or CONHR;
Y is CF 3 , F, I, Br, Cl, CN, C(R) 3 or Sn(R) 3 ;
Q 1 and Q 2 are independently of each other a hydrogen, alkyl, F, Cl, Br, I, CF 3 , CN, C(R) 3 , Sn(R) 3 , N(R) 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R, SR,
Q 3 and Q 4 are independently of each other a hydrogen, alkyl, F, Cl, Br, I, CF 3 , CN, CR 3 , SnR 3 , NR 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R or SR;
W 1 is O, NH, NR, NO or S; and
W 2 is N or NO.
or its isomer, pharmaceutically acceptable salt, hydrate, N-oxide or any combination thereof in an amount effective to prevent dry eyes in said subject.
14 . A method of inducing apoptosis in a cancer cell, comprising the step of contacting said cell with the selective androgen receptor modulator compound represented by the structure of formula I:
wherein
X is a bond, O, CH 2 , NH, Se, PR, NO or NR;
G is O or S;
R 1 is CH 3 , CH 2 F, CHF 2 , CF 3 , CH 2 CH 3 , or CF 2 CF 3 ;
T is OH, OR, NHCOCH 3 , or NHCOR;
R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH 2 F, CHF 2 , CF 3 , CF 2 CF 3 , aryl, phenyl, F, Cl, Br, I, alkenyl or OH;
A is a ring selected from:
B is a ring selected from:
wherein A and B cannot simultaneously be a benzene ring;
Z is NO 2 , CN, COOH, COR, NHCOR or CONHR;
Y is CF 3 , F, I, Br, Cl, CN, C(R) 3 or Sn(R) 3 ;
Q 1 and Q 2 are independently of each other a hydrogen, alkyl, F, Cl, Br, I, CF 3 , CN, C(R) 3 , Sn(R) 3 , N(R) 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R, SR,
Q 3 and Q 4 are independently of each other a hydrogen, alkyl, F, Cl, Br, I, CF 3 , CN, CR 3 , SnR 3 , NR 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R or SR;
W 1 is O, NH, NR, NO or S; and
W 2 is N or NO.
or its isomer, pharmaceutically acceptable salt, hydrate, N-oxide or any combination thereof in an amount effective to induce apoptosis in said cancer cell.
15 . A method of binding a selective androgen receptor modulator compound to an androgen receptor, comprising the step of contacting the androgen receptor with the selective androgen receptor modulator compound represented by the structure of formula II:
wherein
X is a bond, O, CH 2 , NH, Se, PR, NO or NR;
G is O or S;
R 1 is CH 3 , CH 2 F, CHF 2 , CF 3 , CH 2 CH 3 , or CF 2 CF 3 ;
T is OH, OR, NHCOCH 3 , or NHCOR;
R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH 2 F, CHF 2 , CF 3 , CF 2 CF 3 ; aryl, phenyl, F, Cl, Br, I, alkenyl or OH;
B is a ring selected from:
Z is NO 2 , CN, COOH, COR, NHCOR or CONHR;
Y is CF 3 , F, I, Br, Cl, CN, C(R) 3 or Sn(R) 3 ;
Q 1 and Q 2 are independently of each other a hydrogen, alkyl, F, Cl, Br, I, CF 3 , CN, C(R) 33 , Sn(R) 3 , N(R) 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R, SR,
Q 3 and Q 4 are independently of each other a hydrogen, alkyl, F, Cl, Br, I, CF 3 , CN, CR 3 , SnR 3 , NR 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R or SR;
W 1 is O, NH, NR, NO or S; and
W 2 is N or NO.
or its isomer, pharmaceutically acceptable salt, hydrate, N-oxide or any combination thereof in an amount effective to bind the selective androgen receptor modulator compound to the androgen receptor.
16 . A method of suppressing spermatogenesis in a subject comprising contacting an androgen receptor of the subject with the selective androgen receptor modulator compound represented by the structure of formula II:
wherein
X is a bond, O, CH 2 , NH, Se, PR, NO or NR;
G is O or S;
R 1 is CH 3 , CH 2 F, CHF 2 , CF 3 , CH 2 CH 3 , or CF 2 CF 3 ;
T is OH, OR, NHCOCH 3 , or NHCOR;
R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH 2 F, CHF 2 , CF 3 , CF 2 CF 3 ; aryl, phenyl, F, Cl, Br, I, alkenyl or OH;
B is a ring selected from:
Z is NO 2 , CN, COOH, COR, NHCOR or CONHR;
Y is CF 3 , F, I, Br, Cl, CN, C(R) 3 or Sn(R) 3 ;
Q 1 and Q 2 are independently of each other a hydrogen, alkyl, F, Cl, Br, I, CF 3 , CN, C(R) 33 , Sn(R) 3 , N(R) 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R, SR,
Q 3 and Q 4 are independently of each other a hydrogen, alkyl, F, Cl, Br, I, CF 3 , CN, CR 3 , SnR 3 , NR 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R or SR;
W 1 is O, NH, NR, NO or S; and
W 2 is N or NO.
or its isomer, pharmaceutically acceptable salt, hydrate, N-oxide or any combination thereof in an amount effective to suppress sperm production.
17 . A method of contraception in a male subject, comprising the step of administering to said subject the selective androgen receptor modulator compound represented by the structure of formula II:
wherein
X is a bond, O, CH 2 , NH, Se, PR, NO or NR;
G is O or S;
R 1 is CH 3 , CH 2 F, CHF 2 , CF 3 , CH 2 CH 3 , or CF 2 CF 3 ;
T is OH, OR, NHCOCH 3 , or NHCOR;
R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH 2 F, CHF 2 , CF 3 , CF 2 CF 3 ; aryl, phenyl, F, Cl, Br, I, alkenyl or OH;
B is a ring selected from:
Z is NO 2 , CN, COOH, COR, NHCOR or CONHR;
Y is CF 3 , F, I, Br, Cl, CN, C(R) 3 or Sn(R) 3 ;
Q 1 and Q 2 are independently of each other a hydrogen, alkyl, F, Cl, Br, I, CF 3 , CN, C(R) 33 , Sn(R) 3 , N(R) 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R, SR,
Q 3 and Q 4 are independently of each other a hydrogen, alkyl, F, Cl, Br, I, CF 3 , CN, CR 3 , SnR 3 , NR 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R or SR;
W 1 is O, NH, NR, NO or S; and
W 2 is N or NO.
or its isomer, pharmaceutically acceptable salt, hydrate, N-oxide or any combination thereof in an amount effective to suppress sperm production in said subject, thereby effecting contraception in said subject.
18 . A method of hormone therapy comprising the step of contacting an androgen receptor of a subject with the selective androgen receptor modulator compound represented by the structure of formula II:
wherein
X is a bond, O, CH 2 , NH, Se, PR, NO or NR;
G is O or S;
R 1 is CH 3 , CH 2 F, CHF 2 , CF 3 , CH 2 CH 3 , or CF 2 CF 3 ;
T is OH, OR, NHCOCH 3 , or NHCOR;
R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH 2 F, CHF 2 , CF 3 , CF 2 CF 3 ; aryl, phenyl, F, Cl, Br, I, alkenyl or OH;
B is a ring selected from:
Z is NO 2 , CN, COOH, COR, NHCOR or CONHR;
Y is CF 3 , F, I, Br, Cl, CN, C(R) 3 or Sn(R) 3 ;
Q 1 and Q 2 are independently of each other a hydrogen, alkyl, F, Cl, Br, I, CF 3 , CN, C(R) 33 , Sn(R) 3 , N(R) 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R, SR,
Q 3 and Q 4 are independently of each other a hydrogen, alkyl, F, Cl, Br, I, CF 3 , CN, CR 3 , SnR 3 , NR 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R or SR;
W 1 is O, NH, NR, NO or S; and
W 2 is N or NO.
or its isomer, pharmaceutically acceptable salt, hydrate, N-oxide or any combination thereof in an amount effective to effect a change in an androgen-dependent condition.
19 . A method of hormone replacement therapy comprising the step of contacting an androgen receptor of a subject with the selective androgen receptor modulator compound represented by the structure of formula II:
wherein
X is a bond, O, CH 2 , NH, Se, PR, NO or NR;
G is O or S;
R 1 is CH 3 , CH 2 F, CHF 2 , CF 3 , CH 2 CH 3 , or CF 2 CF 3 ;
T is OH, OR, NHCOCH 3 , or NHCOR;
R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH 2 F, CHF 2 , CF 3 , CF 2 CF 3 ; aryl, phenyl, F, Cl, Br, I, alkenyl or OH;
B is a ring selected from:
Z is NO 2 , CN, COOH, COR, NHCOR or CONHR;
Y is CF 3 , F, I, Br, Cl, CN, C(R) 3 or Sn(R) 3 ;
Q 1 and Q 2 are independently of each other a hydrogen, alkyl, F, Cl, Br, I, CF 3 , CN, C(R) 33 , Sn(R) 3 , N(R) 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R, SR,
Q 3 and Q 4 are independently of each other a hydrogen, alkyl, F, Cl, Br, I, CF 3 , CN, CR 3 , SnR 3 , NR 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R or SR;
W 1 is O, NH, NR, NO or S; and
W 2 is N or NO.
or its isomer, pharmaceutically acceptable salt, hydrate, N-oxide or any combination thereof in an amount effective to effect a change in an androgen-dependent condition.
20 . A method of treating a subject having a hormone related condition, comprising the step of administering to said subject the selective androgen receptor modulator compound represented by the structure of formula II:
wherein
X is a bond, O, CH 2 , NH, Se, PR, NO or NR;
G is O or S;
R 1 is CH 3 , CH 2 F, CHF 2 , CF 3 , CH 2 CH 3 , or CF 2 CF 3 ;
T is OH, OR, NHCOCH 3 , or NHCOR;
R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH 2 F, CHF 2 , CF 3 , CF 2 CF 3 ; aryl, phenyl, F, Cl, Br, I, alkenyl or OH;
B is a ring selected from:
Z is NO 2 , CN, COOH, COR, NHCOR or CONHR;
Y is CF 3 , F, I, Br, Cl, CN, C(R) 3 or Sn(R) 3 ;
Q 1 and Q 2 are independently of each other a hydrogen, alkyl, F, Cl, Br, I, CF 3 , CN, C(R) 33 , Sn(R) 3 , N(R) 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R, SR,
Q 3 and Q 4 are independently of each other a hydrogen, alkyl, F, Cl, Br, I, CF 3 , CN, CR 3 , SnR 3 , NR 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R or SR;
W 1 is O, NH, NR, NO or S; and
W 2 is N or NO.
or its isomer, pharmaceutically acceptable salt, hydrate, N-oxide or any combination thereof in an amount effective to effect a change in an androgen-dependent condition.
21 . A method of treating a subject suffering from prostate cancer, comprising the step of administering to said subject the selective androgen receptor modulator compound represented by the structure of formula II:
wherein
X is a bond, O, CH 2 , NH, Se, PR, NO or NR;
G is O or S;
R 1 is CH 3 , CH 2 F, CHF 2 , CF 3 , CH 2 CH 3 , or CF 2 CF 3 ;
T is OH, OR, NHCOCH 3 , or NHCOR;
R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH 2 F, CHF 2 , CF 3 , CF 2 CF 3 ; aryl, phenyl, F, Cl, Br, I, alkenyl or OH;
B is a ring selected from:
Z is NO 2 , CN, COOH, COR, NHCOR or CONHR;
Y is CF 3 , F, I, Br, Cl, CN, C(R) 3 or Sn(R) 3 ;
Q 1 and Q 2 are independently of each other a hydrogen, alkyl, F, Cl, Br, I, CF 3 , CN, C(R) 33 , Sn(R) 3 , N(R) 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R, SR,
Q 3 and Q 4 are independently of each other a hydrogen, alkyl, F, Cl, Br, I, CF 3 , CN, CR 3 , SnR 3 , NR 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R or SR;
W 1 is O, NH, NR, NO or S; and
W 2 is N or NO.
or its isomer, pharmaceutically acceptable salt, hydrate, N-oxide or any combination thereof in an amount effective to treat prostate cancer in said subject.
22 . A method of preventing prostate cancer in a subject, comprising the step of administering to said subject the selective androgen receptor modulator compound represented by the structure of formula II:
wherein
X is a bond, O, CH 2 , NH, Se, PR, NO or NR;
G is O or S;
R 1 is CH 3 , CH 2 F, CHF 2 , CF 3 , CH 2 CH 3 , or CF 2 CF 3 ;
T is OH, OR, NHCOCH 3 , or NHCOR;
R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH 2 F, CHF 2 , CF 3 , CF 2 CF 3 ; aryl, phenyl, F, Cl, Br, I, alkenyl or OH;
B is a ring selected from:
Z is NO 2 , CN, COOH, COR, NHCOR or CONHR;
Y is CF 3 , F, I, Br, Cl, CN, C(R) 3 or Sn(R) 3 ;
Q 1 and Q 2 are independently of each other a hydrogen, alkyl, F, Cl, Br, I, CF 3 , CN, C(R) 33 , Sn(R) 3 , N(R) 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R, SR,
Q 3 and Q 4 are independently of each other a hydrogen, alkyl, F, Cl, Br, I, CF 3 , CN, CR 3 , SnR 3 , NR 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R or SR;
W 1 is O, NH, NR, NO or S; and
W 2 is N or NO.
or its isomer, pharmaceutically acceptable salt, hydrate, N-oxide or any combination thereof in an amount effective to prevent prostate cancer in said subject.
23 . A method of delaying the progression of prostate cancer in a subject suffering from prostate cancer, comprising the step of administering to said subject the selective androgen receptor modulator compound represented by the structure of formula II:
wherein
X is a bond, O, CH 2 , NH, Se, PR, NO or NR;
G is O or S;
R 1 is CH 3 , CH 2 F, CHF 2 , CF 3 , CH 2 CH 3 , or CF 2 CF 3 ;
T is OH, OR, NHCOCH 3 , or NHCOR;
R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH 2 F, CHF 2 , CF 3 , CF 2 CF 3 ; aryl, phenyl, F, Cl, Br, I, alkenyl or OH;
B is a ring selected from:
Z is NO 2 , CN, COOH, COR, NHCOR or CONHR;
Y is CF 3 , F, I, Br, Cl, CN, C(R) 3 or Sn(R) 3 ;
Q 1 and Q 2 are independently of each other a hydrogen, alkyl; F, Cl, Br, I, CF 3 , CN, C(R) 33 , Sn(R) 3 , N(R) 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R, SR,
Q 3 and Q 4 are independently of each other a hydrogen, alkyl, F, Cl, Br, I, CF 3 , CN, CR 3 , SnR 3 , NR 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R or SR;
W 1 is O, NH, NR, NO or S; and
W 2 is N or NO.
or its isomer, pharmaceutically acceptable salt, hydrate, N-oxide or any combination thereof in an amount effective to delay the progression of prostate cancer in said subject.
24 . A method of preventing the recurrence of prostate cancer in a subject suffering from prostate cancer, comprising the step of administering to said subject the selective androgen receptor modulator compound represented by the structure of formula II:
wherein
X is a bond, O, CH 2 , NH, Se, PR, NO or NR;
G is O or S;
R 1 is CH 3 , CH 2 F, CHF 2 , CF 3 , CH 2 CH 3 , or CF 2 CF 3 ;
T is OH, OR, NHCOCH 3 , or NHCOR;
R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH 2 F, CHF 2 , CF 3 , CF 2 CF 3 ; aryl, phenyl, F, Cl, Br, I, alkenyl or OH;
B is a ring selected from:
Z is NO 2 , CN, COOH, COR, NHCOR or CONHR;
Y is CF 3 , F, I, Br, Cl, CN, C(R) 3 or Sn(R) 3 ;
Q 1 and Q 2 are independently of each other a hydrogen, alkyl, F, Cl, Br, I, CF 3 , CN, C(R) 33 , Sn(R) 3 , N(R) 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R, SR,
Q 3 and Q 4 are independently of each other a hydrogen, alkyl, F, Cl, Br, I, CF 3 , CN, CR 3 , SnR 3 , NR 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R or SR;
W 1 is O, NH, NR, NO or S; and
W 2 is N or NO.
or its isomer, pharmaceutically acceptable salt, hydrate, N-oxide or any combination thereof in an amount effective to prevent the recurrence of prostate cancer in said subject.
25 . A method of treating the recurrence of prostate cancer in a subject suffering from prostate cancer, comprising the step of administering to said subject the selective androgen receptor modulator compound represented by the structure of formula II:
wherein
X is a bond, O, CH 2 , NH, Se, PR, NO or NR;
G is O or S;
R 1 is CH 3 , CH 2 F, CHF 2 , CF 3 , CH 2 CH 3 , or CF 2 CF 3 ;
T is OH, OR, NHCOCH 3 , or NHCOR;
R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH 2 F, CHF 2 , CF 3 , CF 2 CF 3 ; aryl, phenyl, F, Cl, Br, I, alkenyl or OH;
B is a ring selected from:
Z is NO 2 , CN, COOH, COR, NHCOR or CONHR;
Y is CF 3 , F, I, Br, Cl, CN, C(R) 3 or Sn(R) 3 ;
Q 1 and Q 2 are independently of each other a hydrogen, alkyl, F, Cl, Br, I, CF 3 , CN, C(R) 33 , Sn(R) 3 , N(R) 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R, SR,
Q 3 and Q 4 are independently of each other a hydrogen, alkyl, F, Cl, Br, I, CF 3 , CN, CR 3 , SnR 3 , NR 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R or SR;
W 1 is O, NH, NR, NO or S; and
W 2 is N or NO.
or its isomer, pharmaceutically acceptable salt, hydrate, N-oxide or any combination thereof in an amount effective to treat the recurrence of prostate cancer in said subject.
26 . A method of treating a dry eye condition in a subject suffering from dry eyes, comprising the step of administering to said subject the selective androgen receptor modulator compound represented by the structure of formula II:
wherein
X is a bond, O, CH 2 , NH, Se, PR, NO or NR;
G is O or S;
R 1 is CH 3 , CH 2 F, CHF 2 , CF 3 , CH 2 CH 3 , or CF 2 CF 3 ;
T is OH, OR, NHCOCH 3 , or NHCOR;
R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH 2 F, CHF 2 , CF 3 , CF 2 CF 3 ; aryl, phenyl, F, Cl, Br, I, alkenyl or OH;
B is a ring selected from:
Z is NO 2 , CN, COOH, COR, NHCOR or CONHR;
Y is CF 3 , F, I, Br, Cl, CN, C(R) 3 or Sn(R) 3 ;
Q 1 and Q 2 are independently of each other a hydrogen, alkyl, F, Cl, Br, I, CF 3 , CN, C(R) 33 , Sn(R) 3 , N(R) 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R, SR,
Q 3 and Q 4 are independently of each other a hydrogen, alkyl, F, Cl, Br, I, CF 3 , CN, CR 3 , SnR 3 , NR 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R or SR;
W 1 is O, NH, NR, NO or S; and
W 2 is N or NO.
or its isomer, pharmaceutically acceptable salt, hydrate, N-oxide or any combination thereof in an amount effective to treat dry eyes in said subject.
27 . A method of preventing a dry eye condition in a subject, comprising the step of administering to said subject the selective androgen receptor modulator compound represented by the structure of formula II:
wherein
X is a bond, O, CH 2 , NH, Se, PR, NO or NR;
G is O or S;
R 1 is CH 3 , CH 2 F, CHF 2 , CF 3 , CH 2 CH 3 , or CF 2 CF 3 ;
T is OH, OR; NHCOCH 3 , or NHCOR;
R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH 2 F, CHF 2 , CF 3 , CF 2 CF 3 ; aryl, phenyl, F, Cl, Br, I, alkenyl or OH;
B is a ring selected from:
Z is NO 2 , CN, COOH, COR, NHCOR or CONHR;
Y is CF 3 , F, I, Br, Cl, CN, C(R) 3 or Sn(R) 3 ;
Q 1 and Q 2 are independently of each other a hydrogen, alkyl, F, Cl, Br, I, CF 3 , CN, C(R) 33 , Sn(R) 3 , N(R) 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R, SR,
Q 3 and Q 4 are independently of each other a hydrogen, alkyl, F, Cl, Br, I, CF 3 , CN, CR 3 , SnR 3 , NR 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R or SR;
W 1 is O, NH, NR, NO or S; and
W 2 is N or NO.
or its isomer, pharmaceutically acceptable salt, hydrate, N-oxide or any combination thereof in an amount effective to prevent dry eyes in said subject.
28 . A method of inducing apoptosis in a cancer cell, comprising the step of contacting said cell with the selective androgen receptor modulator compound represented by the structure of formula II:
wherein
X is a bond, O, CH 2 , NH, Se, PR, NO or NR;
G is O or S;
R 1 is CH 3 , CH 2 F, CHF 2 , CF 3 , CH 2 CH 3 , or CF 2 CF 3 ;
T is OH, OR, NHCOCH 3 , or NHCOR;
R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH 2 F, CHF 2 , CF 3 , CF 2 CF 3 ; aryl, phenyl, F, Cl, Br, I, alkenyl or OH;
B is a ring selected from:
Z is NO 2 , CN, COOH, COR, NHCOR or CONHR;
Y is CF 3 , F, I, Br, Cl, CN, C(R) 3 or Sn(R) 3 ;
Q 1 and Q 2 are independently of each other a hydrogen, alkyl, F, Cl, Br, I, CF 3 , CN, C(R) 33 , Sn(R) 3 , N(R) 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R, SR,
Q 3 and Q 4 are independently of each other a hydrogen, alkyl, F, Cl, Br, I, CF 3 , CN, CR 3 , SnR 3 , NR 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R or SR;
W 1 is O, NH, NR, NO or S; and
W 2 is N or NO.
or its isomer, pharmaceutically acceptable salt, hydrate, N-oxide or any combination thereof in an amount effective to induce apoptosis in said cancer cell.
29 . A method of binding a selective androgen receptor modulator compound to an androgen receptor, comprising the step of contacting the androgen receptor with the selective androgen receptor modulator compound represented by the structure of formula V:
wherein
X is a bond, O, CH 2 , NH, Se, PR, NO or NR;
G is O or S;
R 1 is CH 3 , CH 2 F, CHF 2 , CF 3 , CH 2 CH 3 , or CF 2 CF 3 ;
T is OH, OR, NHCOCH 3 , or NHCOR;
R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH 2 F, CHF 2 , CF 3 , CF 2 CF 3 ; aryl, phenyl, F, Cl, Br, I, alkenyl or OH;
A is a ring selected from:
Z is NO 2 , CN, COOH, COR, NHCOR or CONHR;
Y is CF 3 , F, I, Br, Cl, CN, C(R) 3 or Sn(R) 3 ;
Q 1 and Q 2 are independently of each other a hydrogen, alkyl, F, Cl, Br, I, CF 3 , CN, C(R) 3 , Sn(R) 3 , N(R) 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R, SR,
Q 3 and Q 4 are independently of each other a hydrogen, alkyl, F, Cl, Br, I, CF 3 , CN, C(R) 3 , Sn(R) 3 , N(R) 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R or SR;
W 1 is O, NH, NR, NO or S; and
W 2 is N or NO.
or its isomer, pharmaceutically acceptable salt, hydrate, N-oxide or any combination thereof in an amount effective to bind the selective androgen receptor modulator compound to the androgen receptor.
30 . A method of suppressing spermatogenesis in a subject comprising contacting an androgen receptor of the subject with the selective androgen receptor modulator compound represented by the structure of formula V:
wherein
X is a bond, O, CH 2 , NH, Se, PR, NO or NR;
G is O or S;
R 1 is CH 3 , CH 2 F, CHF 2 , CF 3 , CH 2 CH 3 , or CF 2 CF 3 ;
T is OH, OR, NHCOCH 3 , or NHCOR;
R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH 2 F, CHF 2 , CF 3 , CF 2 CF 3 ; aryl, phenyl, F, Cl, Br, I, alkenyl or OH;
A is a ring selected from:
Z is NO 2 , CN, COOH, COR, NHCOR or CONHR;
Y is CF 3 , F, I, Br, Cl, CN, C(R) 3 or Sn(R) 3 ;
Q 1 and Q 2 are independently of each other a hydrogen, alkyl, F, Cl, Br, I, CF 3 , CN, C(R) 3 , Sn(R) 3 , N(R) 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R, SR,
Q 3 and Q 4 are independently of each other a hydrogen, alkyl, F, Cl, Br, I, CF 3 , CN, C(R) 3 , Sn(R) 3 , N(R) 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R or SR;
W 1 is O, NH, NR, NO or S; and
W 2 is N or NO.
or its isomer, pharmaceutically acceptable salt, hydrate, N-oxide or any combination thereof in an amount effective to suppress sperm production.
31 . A method of contraception in a male subject, comprising the step of administering to said subject the selective androgen receptor modulator compound represented by the structure of formula V:
wherein
X is a bond, O, CH 2 , NH, Se, PR, NO or NR;
G is O or S;
R 1 is CH 3 , CH 2 F, CHF 2 , CF 3 , CH 2 CH 3 , or CF 2 CF 3 ;
T is OH, OR, NHCOCH 3 , or NHCOR;
R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH 2 F, CHF 2 , CF 3 , CF 2 CF 3 ; aryl, phenyl, F, Cl, Br, I, alkenyl or OH;
A is a ring selected from:
Z is NO 2 , CN, COOH, COR, NHCOR or CONHR;
Y is CF 3 , F, I, Br, Cl, CN, C(R) 3 or Sn(R) 3 ;
Q 1 and Q 2 are independently of each other a hydrogen, alkyl, F, Cl, Br, I, CF 3 , CN, C(R) 3 , Sn(R) 3 , N(R) 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R, SR,
Q 3 and Q 4 are independently of each other a hydrogen, alkyl, F, Cl, Br, I, CF 3 , CN, C(R) 3 , Sn(R) 3 , N(R) 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R or SR;
W 1 is O, NH, NR, NO or S; and
W 2 is N or NO.
or its isomer, pharmaceutically acceptable salt, hydrate, N-oxide or any combination thereof in an amount effective to suppress sperm production in said subject, thereby effecting contraception in said subject.
32 . A method of hormone therapy comprising the step of contacting an androgen receptor of a subject with the selective androgen receptor modulator compound represented by the structure of formula V:
wherein
X is a bond, O, CH 2 , NH, Se, PR, NO or NR;
G is O or S;
R 1 is CH 3 , CH 2 F, CHF 2 , CF 3 , CH 2 CH 3 , or CF 2 CF 3 ;
T is OH, OR, NHCOCH 3 , or NHCOR;
R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH 2 F, CHF 2 , CF 3 , CF 2 CF 3 ; aryl, phenyl, F, Cl, Br, I, alkenyl or OH;
A is a ring selected from:
Z is NO 2 , CN, COOH, COR, NHCOR or CONHR;
Y is CF 3 , F, I, Br, Cl, CN, C(R) 3 or Sn(R) 3 ;
Q 1 and Q 2 are independently of each other a hydrogen, alkyl, F, Cl, Br, I, CF 3 , CN, C(R) 3 , Sn(R) 3 , N(R) 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R, SR,
Q 3 and Q 4 are independently of each other a hydrogen, alkyl, F, Cl, Br, I, CF 3 , CN, C(R) 3 , Sn(R) 3 , N(R) 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R or SR;
W 1 is O, NH, NR, NO or S; and
W 2 is N or NO.
or its isomer, pharmaceutically acceptable salt, hydrate, N-oxide or any combination thereof in an amount effective to effect a change in an androgen-dependent condition.
33 . A method of hormone replacement therapy comprising the step of contacting an androgen receptor of a subject with the selective androgen receptor modulator compound represented by the structure of formula V:
wherein
X is a bond, O, CH 2 , NH, Se, PR, NO or NR;
G is O or S;
R 1 is CH 3 , CH 2 F, CHF 2 , CF 3 , CH 2 CH 3 , or CF 2 CF 3 ;
T is OH, OR, NHCOCH 3 , or NHCOR;
R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH 2 F, CHF 2 , CF 3 , CF 2 CF 3 ; aryl, phenyl, F, Cl, Br, I, alkenyl or OH;
A is a ring selected from:
Z is NO 2 , CN, COOH, COR, NHCOR or CONHR;
Y is CF 3 , F, I, Br, Cl, CN, C(R) 3 or Sn(R) 3 ;
Q 1 and Q 2 are independently of each other a hydrogen, alkyl, F, Cl, Br, I, CF 3 , CN, C(R) 3 , Sn(R) 3 , N(R) 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R, SR,
Q 3 and Q 4 are independently of each other a hydrogen, alkyl, F, Cl, Br, I, CF 3 , CN, C(R) 3 , Sn(R) 3 , N(R) 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R or SR;
W 1 is O, NH, NR, NO or S; and
W 2 is N or NO.
or its isomer, pharmaceutically acceptable salt, hydrate, N-oxide or any combination thereof in an amount effective to effect a change in an androgen-dependent condition.
34 . A method of treating a subject having a hormone related condition, comprising the step of administering to said subject the selective androgen receptor modulator compound represented by the structure of formula V:
wherein
X is a bond, O, CH 2 , NH, Se, PR, NO or NR;
G is O or S;
R 1 is CH 3 , CH 2 F, CHF 2 , CF 3 , CH 2 CH 3 , or CF 2 CF 3 ;
T is OH, OR, NHCOCH 3 , or NHCOR;
R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH 2 F, CHF 2 , CF 3 , CF 2 CF 3 ; aryl, phenyl, F, Cl, Br, I, alkenyl or OH;
A is a ring selected from:
Z is NO 2 , CN, COOH, COR, NHCOR or CONHR;
Y is CF 3 , F, I, Br, Cl, CN, C(R) 3 or Sn(R) 3 ;
Q 1 and Q 2 are independently of each other a hydrogen, alkyl, F, Cl, Br, I, CF 3 , CN, C(R) 3 , Sn(R) 3 , N(R) 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R, SR,
Q 3 and Q 4 are independently of each other a hydrogen, alkyl, F, Cl, Br, I, CF 3 , CN, C(R) 3 , Sn(R) 3 , N(R) 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R or SR;
W 1 is O, NH, NR, NO or S; and
W 2 is N or NO.
or its isomer, pharmaceutically acceptable salt, hydrate, N-oxide or any combination thereof in an amount effective to effect a change in an androgen-dependent condition.
35 . A method of treating a subject suffering from prostate cancer, comprising the step of administering to said subject the selective androgen receptor modulator compound represented by the structure of formula V:
wherein
X is a bond, O, CH 2 , NH, Se, PR, NO or NR;
G is O or S;
R 1 is CH 3 , CH 2 F, CHF 2 , CF 3 , CH 2 CH 3 , or CF 2 CF 3 ;
T is OH, OR, NHCOCH 3 , or NHCOR;
R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH 2 F, CHF 2 , CF 3 , CF 2 CF 3 ; aryl, phenyl, F, Cl, Br, I, alkenyl or OH;
A is a ring selected from:
Z is NO 2 , CN, COOH, COR, NHCOR or CONHR;
Y is CF 3 , F, I, Br, Cl, CN, C(R) 3 or Sn(R) 3 ;
Q 1 and Q 2 are independently of each other a hydrogen, alkyl, F, Cl, Br, I, CF 3 , CN, C(R) 3 , Sn(R) 3 , N(R) 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R, SR,
Q 3 and Q 4 are independently of each other a hydrogen, alkyl, F, Cl, Br, I, CF 3 , CN, C(R) 3 , Sn(R) 3 , N(R) 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R or SR;
W 1 is O, NH, NR, NO or S; and
W 2 is N or NO.
or its isomer, pharmaceutically acceptable salt, hydrate, N-oxide or any combination thereof in an amount effective to treat prostate cancer in said subject.
36 . A method of preventing prostate cancer in a subject, comprising the step of administering to said subject the selective androgen receptor modulator compound represented by the structure of formula V:
wherein
X is a bond, O, CH 2 , NH, Se, PR, NO or NR;
G is O or S;
R 1 is CH 3 , CH 2 F, CHF 2 , CF 3 , CH 2 CH 3 , or CF 2 CF 3 ;
T is OH, OR, NHCOCH 3 , or NHCOR;
R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH 2 F, CHF 2 , CF 3 , CF 2 CF 3 ; aryl, phenyl, F, Cl, Br, I, alkenyl or OH;
A is a ring selected from:
Z is NO 2 , CN, COOH, COR, NHCOR or CONHR;
Y is CF 3 , F, I, Br, Cl, CN, C(R) 3 or Sn(R) 3 ;
Q 1 and Q 2 are independently of each other a hydrogen, alkyl, F, Cl, Br, I, CF 3 , CN, C(R) 3 , Sn(R) 3 , N(R) 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R, SR,
Q 3 and Q 4 are independently of each other a hydrogen, alkyl, F, Cl, Br, I, CF 3 , CN, C(R) 3 , Sn(R) 3 , N(R) 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R or SR;
W 1 is O, NH, NR, NO or S; and
W 2 is N or NO.
or its isomer, pharmaceutically acceptable salt, hydrate, N-oxide or any combination thereof in an amount effective to prevent prostate cancer in said subject.
37 . A method of delaying the progression of prostate cancer in a subject suffering from prostate cancer, comprising the step of administering to said subject the selective androgen receptor modulator compound represented by the structure of formula V:
wherein
X is a bond, O, CH 2 , NH, Se, PR, NO or NR;
G is O or S;
R 1 is CH 3 , CH 2 F, CHF 2 , CF 3 , CH 2 CH 3 , or CF 2 CF 3 ;
T is OH, OR, NHCOCH 3 , or NHCOR;
R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH 2 F, CHF 2 , CF 3 , CF 2 CF 3 ; aryl, phenyl, F, Cl, Br, I, alkenyl or OH;
A is a ring selected from:
Z is NO 2 , CN, COOH, COR, NHCOR or CONHR;
Y is CF 3 , F, I, Br, Cl, CN, C(R) 3 or Sn(R) 3 ;
Q 1 and Q 2 are independently of each other a hydrogen, alkyl, F, Cl, Br, I, CF 3 , CN, C(R) 3 , Sn(R) 3 , N(R) 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R, SR,
Q 3 and Q 4 are independently of each other a hydrogen, alkyl, F, Cl, Br, I, CF 3 , CN, C(R) 3 , Sn(R) 3 , N(R) 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R or SR;
W 1 is O, NH, NR, NO or S; and
W 2 is N or NO.
or its isomer, pharmaceutically acceptable salt, hydrate, N-oxide or any combination thereof in an amount effective to delay the progression of prostate cancer in said subject.
38 . A method of preventing the recurrence of prostate cancer in a subject suffering from prostate cancer, comprising the step of administering to said subject the selective androgen receptor modulator compound represented by the structure of formula V:
wherein
X is a bond, O, CH 2 , NH, Se, PR, NO or NR;
G is O or S;
R 1 is CH 3 , CH 2 F, CHF 2 , CF 3 , CH 2 CH 3 , or CF 2 CF 3 ;
T is OH, OR, NHCOCH 3 , or NHCOR;
R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH 2 F, CHF 2 , CF 3 , CF 2 CF 3 ; aryl, phenyl, F, Cl, Br, I, alkenyl or OH;
A is a ring selected from:
Z is NO 2 , CN, COOH, COR, NHCOR or CONHR;
Y is CF 3 , F, I, Br, Cl, CN, C(R) 3 or Sn(R) 3 ;
Q 1 and Q 2 are independently of each other a hydrogen, alkyl, F, Cl, Br, I, CF 3 , CN, C(R) 3 , Sn(R) 3 , N(R) 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R, SR,
Q 3 and Q 4 are independently of each other a hydrogen, alkyl, F, Cl, Br, I, CF 3 , CN, C(R) 3 , Sn(R) 3 , N(R) 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R or SR;
W 1 is O, NH, NR, NO or S; and
W 2 is N or NO.
or its isomer, pharmaceutically acceptable salt, hydrate, N-oxide or any combination thereof in an amount effective to prevent the recurrence of prostate cancer in said subject.
39 . A method of treating the recurrence of prostate cancer in a subject suffering from prostate cancer, comprising the step of administering to said subject the selective androgen receptor modulator compound represented by the structure of formula V:
wherein
X is a bond, O, CH 2 , NH, Se, PR, NO or NR;
G is O or S;
R 1 is CH 3 , CH 2 F, CHF 2 , CF 3 , CH 2 CH 3 , or CF 2 CF 3 ;
T is OH, OR, NHCOCH 3 , or NHCOR;
R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH 2 F, CHF 2 , CF 3 , CF 2 CF 3 ; aryl, phenyl, F, Cl, Br, I, alkenyl or OH;
A is a ring selected from:
Z is NO 2 , CN, COOH, COR, NHCOR or CONHR;
Y is CF 3 , F, I, Br, Cl, CN, C(R) 3 or Sn(R) 3 ;
Q 1 and Q 2 are independently of each other a hydrogen, alkyl, F, Cl, Br, I, CF 3 , CN, C(R) 3 , Sn(R) 3 , N(R) 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R, SR,
Q 3 and Q 4 are independently of each other a hydrogen, alkyl, F, Cl, Br, I, CF 3 , CN, C(R) 3 , Sn(R) 3 , N(R) 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R or SR;
W 1 is O, NH, NR, NO or S; and
W 2 is Nor NO.
or its isomer, pharmaceutically acceptable salt, hydrate, N-oxide or any combination thereof in an amount effective to treat the recurrence of prostate cancer in said subject.
40 . A method of treating a dry eye condition in a subject suffering from dry eyes, comprising the step of administering to said subject the selective androgen receptor modulator compound represented by the structure of formula V:
wherein
X is a bond, O, CH 2 , NH, Se, PR, NO or NR;
G is O or S;
R 1 is CH 3 , CH 2 F, CHF 2 , CF 3 , CH 2 CH 3 , or CF 2 CF 3 ;
T is OH, OR, NHCOCH 3 , or NHCOR;
R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH 2 F, CHF 2 , CF 3 , CF 2 CF 3 ; aryl, phenyl, F, Cl, Br, I, alkenyl or OH;
A is a ring selected from:
Z is NO 2 , CN, COOH, COR, NHCOR or CONHR;
Y is CF 3 , F, I, Br, Cl, CN, C(R) 3 or Sn(R) 3 ;
Q 1 and Q 2 are independently of each other a hydrogen, alkyl, F, Cl, Br, I, CF 3 , CN, C(R) 3 , Sn(R) 3 , N(R) 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R, SR,
Q 3 and Q 4 are independently of each other a hydrogen, alkyl, F, Cl, Br, I, CF 3 , CN, C(R) 3 , Sn(R) 3 , N(R) 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R or SR;
W 1 is O, NH, NR, NO or S; and
W 2 is N or NO.
or its isomer, pharmaceutically acceptable salt, hydrate, N-oxide or any combination thereof in an amount effective to treat dry eyes in said subject.
41 . A method of preventing a dry eye condition in a subject, comprising the step of administering to said subject the selective androgen receptor modulator compound represented by the structure of formula V:
wherein
X is a bond, O, CH 2 , NH, Se, PR, NO or NR;
G is O or S;
R 1 is CH 3 , CH 2 F, CHF 2 , CF 3 , CH 2 CH 3 , or CF 2 CF 3 ;
T is OH, OR, NHCOCH 3 , or NHCOR;
R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH 2 F, CHF 2 , CF 3 , CF 2 CF 3 ; aryl, phenyl, F, Cl, Br, I, alkenyl or OH;
A is a ring selected from:
Z is NO 2 , CN, COOH, COR, NHCOR or CONHR;
Y is CF 3 , F, I, Br, Cl, CN, C(R) 3 or Sn(R) 3 ;
Q 1 and Q 2 are independently of each other a hydrogen, alkyl, F, Cl, Br, I, CF 3 , CN, C(R) 3 , Sn(R) 3 , N(R) 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R, SR,
Q 3 and Q 4 are independently of each other a hydrogen, alkyl, F, Cl, Br, I, CF 3 , CN, C(R) 3 , Sn(R) 3 , N(R) 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R or SR;
W 1 is O, NH, NR, NO or S; and
W 2 is N or NO.
or its isomer, pharmaceutically acceptable salt, hydrate, N-oxide or any combination thereof in an amount effective to prevent dry eyes in said subject.
42 . A method of inducing apoptosis in a cancer cell, comprising the step of contacting said cell with the selective androgen receptor modulator compound represented by the structure of formula V:
wherein
X is a bond, O, CH 2 , NH, Se, PR, NO or NR;
G is O or S;
R 1 is CH 3 , CH 2 F, CHF 2 , CF 3 , CH 2 CH 3 , or CF 2 CF 3 ;
T is OH, OR, NHCOCH 3 , or NHCOR;
R is alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, CH 2 F, CHF 2 , CF 3 , CF 2 CF 3 ; aryl, phenyl, F, Cl, Br, I, alkenyl or OH;
A is a ring selected from:
Z is NO 2 , CN, COOH, COR, NHCOR or CONHR;
Y is CF 3 , F, I, Br, Cl, CN, C(R) 3 or Sn(R) 3 ;
Q 1 and Q 2 are independently of each other a hydrogen, alkyl, F, Cl, Br, I, CF 3 , CN, C(R) 3 , Sn(R) 3 , N(R) 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R, SR,
Q 3 and Q 4 are independently of each other a hydrogen, alkyl, F, Cl, Br, I, CF 3 , CN, C(R) 3 , Sn(R) 3 , N(R) 2 , NHCOCH 3 , NHCOCF 3 , NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH 3 , NHCSCF 3 , NHCSR, NHSO 2 CH 3 , NHSO 2 R, OR, COR, OCOR, OSO 2 R, SO 2 R or SR;
W 1 is O, NH, NR, NO or S; and
W 2 is N or NO.
or its isomer, pharmaceutically acceptable salt, hydrate, N-oxide or any combination thereof in an amount effective to induce apoptosis in said cancer cell.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.